Sangamo regains hemophilia gene therapies from Shire

Sangamo BioSciences Inc. (NASDAQ:SGMO) fell $0.50 to $7.15 after regaining exclusive, worldwide rights from Shire plc (LSE:SHP; NASDAQ:SHPG) to preclinical zinc finger DNA-binding protein (ZFP) programs for hemophilia A and B. Sangamo plans to file INDs for its hemophilia B program by YE15 and its hemophilia A program in 2016. Shire holds a right of first negotiation to re-license both programs.

Under the revised partnership, Shire will retain rights to develop ZFP therapeutics for Huntington's disease and against one undisclosed target. Rights to the remaining targets under the original collaboration will revert to Sangamo. ...